SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 10-Q

(Mark One)


[x] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
     Act of 1934

For the quarterly period ended December 31, 2002

[ ] Transition report pursuant to Section 13 or 15(d) of the Securities
     Exchange Act of 1934

For the transition period from ___________________ to ___________________


Commission file number: 0-16594

                        MEDICAL TECHNOLOGY SYSTEMS, INC.
--------------------------------------------------------------------------------
             (Exact Name of Registrant as Specified in Its Charter)


              DELAWARE                                          59-2740462
------------------------------------                    -----------------------
   (State or other jurisdiction of                          (I.R.S.) Employer
   Incorporation or Organization)                          Identification No.)


              12920 Automobile Boulevard, Clearwater, Florida 33762
--------------------------------------------------------------------------------
                    (Address of Principal Executive Offices)


                                  727-576-6311
--------------------------------------------------------------------------------
              (Registrant's Telephone Number, Including Area Code)


--------------------------------------------------------------------------------
              (Former Name, Former Address and Former Fiscal Year,
                          if changed since last report)



     Indicate by check mark  whether the  registrant:  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant  was required to file such  reports) and (2) has been subject to such
filing requirements for the past 90 days.    Yes  X    No
                                                -----     -----


     Indicate by check mark whether the Registrant is an  accelerated  filer (as
defined in Rule 12b-2 of the Exchange Act).    Yes         No    X
                                                   -----       -----

     As of December 31, 2002,  the  Registrant  had  4,371,523  shares of common
stock, $.01 par value per share, issued and outstanding.


                                      10Q-1


<PAGE>



                                       i.
                MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES


                                      Index

                                                                          Page
Part I - Financial Information


Item 1.   Financial Statements

          Condensed Consolidated Balance Sheets -
              December 31, 2002 and March 31, 2002......................       1


          Condensed Consolidated Statements of Earnings -
              Three and Nine Months Ended December 31, 2002 and 2001....       2


          Condensed Consolidated Statements of Changes in Stockholders' Equity -
              Nine Months Ended December 31, 2002.......................       3


          Condensed Consolidated Statements of Cash Flows -
              Nine Months Ended December 31, 2002 and 2001..............       4


          Notes to Condensed Consolidated Financial Statements..........  5 - 12


Item 2.   Management's Discussion and Analysis of Financial
              Condition and Results of Operations....................... 13 - 16


Item 3.   Quantitative and Qualitative Disclosures About Market Risk....      17


Item 4.   Controls and Procedures.......................................      17


Part II - Other Information


Item 6.   Exhibits and Reports on Form 8-K..............................      18


          Signatures....................................................      18


Certifications.......................................................... 19 - 22



<PAGE>
                                       1




Item 1.  Financial Statements


                    PART 1 - FINANCIAL INFORMATION

          MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
                CONDENSED CONSOLIDATED BALANCE SHEETS
                            (In Thousands)


                                     ASSETS
<TABLE>
<CAPTION>
                                                                         December 31,                March 31,
                                                                             2002                      2002
                                                                       ----------------          -----------------
                                                                         (Unaudited)
<S>                                                                    <C>                        <C>
Current Assets:
     Cash                                                              $           122            $           410
     Accounts Receivable, Net                                                    4,372                      3,456
     Inventories                                                                 3,072                      2,212
     Prepaids and Other                                                            261                        199
     Deferred Tax Benefits                                                       1,232                      1,232
                                                                       ----------------          -----------------
     Total Current Assets                                                        9,059                      7,509

Property and Equipment, Net                                                      2,789                      2,425
Other Assets, Net                                                                2,842                      2,477
Deferred Tax Benefits                                                            2,404                      3,104
                                                                       ----------------          -----------------

Total Assets                                                           $        17,094            $        15,515
                                                                       ================          =================


                      LIABILITIES AND STOCKHOLDERS' EQUITY


Current Liabilities:
     Current Maturities of Long-Term Debt                              $         1,168           $            968
     Accounts Payable and Accrued Liabilities                                    3,663                      3,267
                                                                       ----------------          -----------------
     Total Current Liabilities                                                   4,831                      4,235

Long-Term Debt, Less Current Maturities                                          7,552                     10,812
                                                                       ----------------          -----------------
Total Liabilities                                                               12,383                     15,047
                                                                       ----------------          -----------------

Stockholders' Equity:
     Common Stock                                                                   44                         43
     Preferred Stock                                                                 1                          0
     Capital In Excess of Par Value                                             11,897                      8,806
     Accumulated Deficit                                                        (6,903)                    (8,053)
     Treasury Stock                                                               (328)                      (328)
                                                                       ----------------          -----------------
     Total Stockholders' Equity                                                  4,711                        468
                                                                       ----------------          -----------------
     Total Liabilities and Stockholders' Equity                        $        17,094           $         15,515
                                                                       ================          =================



The accompanying notes are an integral part of these financial statements.

</TABLE>


<PAGE>
                                       2


                MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
                  CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
                (In Thousands; Except Earnings Per Share Amounts)

                                   (Unaudited)


<TABLE>
<CAPTION>
                                                               Three Months Ended                  Nine Months Ended
                                                                  December 31,                        December 31,
                                                         -------------------------------     -------------------------------
                                                              2002              2001              2002              2001
                                                         --------------    -------------     --------------    -------------
<S>                                                      <C>               <C>               <C>               <C>
Revenue:
      Net Sales                                          $       7,694     $      6,192      $      21,320     $     18,059

Costs and Expenses:
      Cost of Sales                                              4,573            3,686             12,985           10,661
      Selling, General and Administrative                        1,822            1,206              4,834            3,862
      Depreciation and Amortization                                243              227                679              684
                                                         --------------    -------------     --------------    -------------
Total Costs and Expenses                                         6,638            5,119             18,498           15,207
                                                         --------------    -------------     --------------    -------------

Operating Profit                                                 1,056            1,073              2,822            2,852

Other Expenses
      Interest Expense                                             219              219                668              700
      Amortization of:
          Financing Costs                                           89                0                178                0
          Original Issue Discount                                   62                0                127                0
                                                         --------------    -------------     --------------    -------------
Total Other Expenses                                               370              219                973              700

Income Before Income Taxes                                         686              854              1,849            2,152

Income Tax Expense                                                 261              320                699              796
                                                         --------------    -------------     --------------    -------------

Net Income                                                         425              534              1,150            1,356

Non-Cash Constructive Dividend Related to
      Beneficial Conversion Feature of Convertible
          Preferred Stock                                            0                0                347                0

Convertible Preferred Stock Dividends                               55                0                113                0
                                                         --------------    -------------     --------------    -------------

Net Income Available to Common Stockholders              $         370     $        534      $         690     $      1,356
                                                         ==============    =============     ==============    =============

Net Income Per Basic Common Share                        $        0.07     $       0.12      $        0.15     $       0.32
                                                         ==============    =============     ==============    =============

Net Income Per Diluted Common Share                      $        0.06     $       0.12      $        0.12     $       0.30
                                                         ==============    =============     ==============    =============



The accompanying notes are an integral part of these financial statements.


</TABLE>


<PAGE>
                                       3



                MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
      CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
                       SIX MONTHS ENDED DECEMBER 31, 2002
                                 (In Thousands)
                                   (Unaudited)


<TABLE>
<CAPTION>
                                     Common Stock       Preferred Stock
                                    $.01 Par Value      $.001 Par Value       Capital                                     Total
                                 --------------------  -----------------     In Excess     Accumulated    Treasury    Stockholder's
                                   Shares    Amount     Shares   Amount    of Par Value      Deficit        Stock        Equity
                                 ---------- --------   -------- --------  --------------  -------------  ----------  ---------------
<S>                              <C>         <C>         <C>     <C>        <C>             <C>            <C>         <C>

Balance, March 31, 2002          4,331,161   $  43           0   $   0      $    8,806      $ (8,053)     $  (328)      $      468

Stock Options and Warrants
    Exercised                       40,362       1                                   9                                          10

Warrants Issued                                                                  1,564                                       1,564

Preferred Stock Issued                                   2,000       1           1,999                                       2,000

Costs Related to Equity Issued                                                    (368)                                       (368)

Convertible Preferred Stock
     Dividend                                                                     (113)                                       (113)

Non-Cash Constructive Dividend
 Related to Beneficial Conversion
  Feature of Convertible
   Preferred Stock                                                                (347)                                       (347)

Amortization of Non-Cash
 Constructive Dividend related to
  Beneficial Conversion Feature
   of Convertible Preferred Stock                                                  347                                         347

Net Income for Nine Months Ended
    December 31, 2002                                                                          1,150                         1,150
                                 ---------- --------   -------- --------  --------------  -------------  ----------  ---------------


Balance December 31, 2002        4,371,523   $  44       2,000   $   1     $    11,897      $ (6,903)     $  (328)      $    4,711
                                 ========== ========   ======== ========  =============   =============  ==========  ===============

</TABLE>


<PAGE>
                                       4


                MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (In Thousands)
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                              Nine Months Ended
                                                                                                 December 31,
                                                                                    -------------------------------------
                                                                                         2002                    2001
                                                                                    -------------           -------------
<S>                                                                                 <C>                     <C>
Operating Activities
    Net Income                                                                      $      1,150            $      1,356
                                                                                    -------------           -------------
    Adjustments to Reconcile Net Income to Net Cash
       Provided by Operating Activities:
       Obsolete Inventory Written Off                                                         47                       0
       Deferred Compensation                                                                   0                      29
       Amortization of Original Issue Discount                                               127                       0
       Amortization of Deferred Financing Costs                                              179                       0
       Depreciation and Amortization                                                         681                     684
       Income Tax Expense                                                                    699                     796
       (Increase) Decrease in:
           Accounts Receivable                                                              (916)                   (335)
           Inventories                                                                      (223)                    229
           Prepaids and Other                                                                (63)                    (96)
       Increase (Decrease) in:
           Accounts Payable and Other Accrued Liabilities                                    396                    (364)
                                                                                    -------------           -------------
    Total Adjustments                                                                        927                     943
                                                                                    -------------           -------------
    Net Cash Provided by Operating Activities                                              2,077                   2,299
                                                                                    -------------           -------------

Investing Activities
    Expended for Property and Equipment                                                     (742)                   (732)
    Expended for Product Development                                                        (384)                   (515)
    Expended for Patents and Other Assets                                                    (52)                    (27)
                                                                                    -------------           -------------
    Net Cash Used by Investing Activities                                                 (1,178)                 (1,274)
                                                                                    -------------           -------------

Financing Activities
    Payments on Notes Payable and Long-Term Debt                                         (12,089)                   (794)
    Net Advances on Revolving Line of Credit                                               3,445                       0
    Borrowing on Term Loans and Subordinated Notes                                         6,700                       0
    Issuance of Convertible Preferred Stock                                                2,000                       0
    Expended for Financing Costs                                                          (1,130)                      0
    Dividends on Convertible Preferred Stock                                                (113)                      0
    Advances (To) Affiliates - Discontinued Operations                                         0                    (161)
                                                                                    -------------           -------------
    Net Cash Used by Financing Activities                                                 (1,187)                   (955)
                                                                                    -------------           -------------

Net Increase (Decrease) in Cash                                                             (288)                     70
Cash at Beginning of Period                                                                  410                      92
                                                                                    -------------           -------------
Cash at End of Period                                                               $        122            $        162
                                                                                    =============           =============

</TABLE>

See Note L for supplemental disclosures of other cash flow information.

The accompanying notes are an integral part of these financial statements.



<PAGE>
                                       5


NOTE A - BASIS OF PRESENTATION

     The accompanying unaudited condensed consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the
United States of America (US GAAP) for interim  financial  information  and with
the  instructions  to Form 10-Q and Article 10 of Regulation  S-X.  Accordingly,
they do not include all of the information and notes required by the US GAAP for
complete  financial  statements.  In the opinion of management,  all adjustments
(consisting  of  normal  recurring  accruals)  considered  necessary  for a fair
presentation have been included. Operating results for the three- and nine-month
periods ended  December 31, 2002 are not  necessarily  indicative of the results
that may be expected for the year ended March 31, 2003. The unaudited  condensed
consolidated  financial  statements  should  be read  in  conjunction  with  the
consolidated  financial  statements and notes thereto  included in the Company's
annual report on Form 10-K for the year ended March 31, 2002.

     The  unaudited  condensed  consolidated  financial  statements  include the
accounts of the Company and its subsidiary,  MTS Packaging  Systems,  Inc. ("MTS
Packaging").  All other  subsidiaries  of the  Company  did not have  operations
during the three and nine months ended December 31, 2002 and 2001.


NOTE B - INVENTORIES

         The components of inventory consist of the following:

<TABLE>
<CAPTION>
                                                                    December 31,           March 31,
                                                                        2002                  2002
                                                                  ----------------     ----------------
                                                                              (In Thousands)
               <S>                                                <C>                   <C>
               Raw Materials                                      $        1,562        $          964
               Finished Goods and Work in Progress                         1,597                 1,288
               Less:  Inventory Valuation Allowance                          (87)                 (40)
                                                                  ----------------     ----------------
                                                                  $        3,072        $        2,212
                                                                  ================     ================
</TABLE>


     Inventories  are  stated  at the  lower of cost  (first-in,  first-out)  or
market.


NOTE C - EARNINGS PER SHARE

     Net Income per common share is computed by dividing net income available to
common  shareholders by the basic and diluted  weighted average number of shares
of common stock outstanding.  The number of shares of common stock, for purposes
of the basic earnings per share  computation,  include 566,517 shares that could
result from the exercise of warrants exercisable at $.01 per share by the holder
of the warrants.  (See Note F) For diluted weighted average shares  outstanding,
the  Company  used the  treasury  stock  method to  calculate  the Common  Stock
equivalents  that the stock options and warrants would  represent.  In addition,
the  convertible  preferred  stock has been treated as if it had been  converted
into common stock on the date of issuance.

     The CEO of the Company  may elect to receive  shares of  restricted  common
stock  in  lieu  of  cash  compensation  according  to the  terms  of his  Stock
Appreciation  Rights  Agreement  with the  Company.  In December  2002,  the CEO
elected to receive  cash for all amounts  due  pursuant  to the  agreement,  and
therefore,  the number of shares he may have  received has not been  included in
the calculation of earnings per share.


<PAGE>
                                       6


     The  following  table  sets forth the  computation  of income per basic and
diluted common share:

<TABLE>
<CAPTION>
                                                            Three Months Ended                Nine Months Ended
                                                       ------------------------------   -------------------------------
                                                        December 31,     December 31,    December 31,      December 31,
                                                            2002             2001            2002             2001
                                                       --------------   -------------   --------------   --------------
<S>                                                    <C>              <C>             <C>              <C>
Numerator:

 Net Income                                            $        425     $       534     $      1,150     $      1,356

   Minus:
     Constructive Dividend Related to Beneficial
       Conversion Feature of the Convertible
          Preferred Stock                                         0               0              347                0

      Convertible Preferred Stock Dividend                       55               0              113                0
                                                       ---------------  --------------  ---------------  ---------------

Net Income Available to Common Stockholders                     370             534              690            1,356
                                                       ---------------  --------------  ---------------  ---------------

Denominator:

   Weighted Average Shares Outstanding - Basic                4,936           4,325            4,744            4,289

   Add: Effect of Dilutive Warrants and Options                 271             316              371              199

   Effect of Conversion of Convertible Preferred
     Stock into Common Stock                                    847               0              579                0
                                                       ---------------  --------------  ---------------  ---------------

   Weighted Average Shares Outstanding - Diluted              6,054           4,641            5,694            4,488
                                                       ===============  ==============  ===============  ===============

Net Income Per Basic Common Share                      $       0.07     $      0.12     $       0.15     $       0.32
                                                       ===============  ==============  ===============  ===============

Net Income Per Diluted Common Share                    $       0.06     $      0.12     $       0.12     $       0.30
                                                       ===============  ==============  ===============  ===============

</TABLE>


     Certain  provisions  of the  warrants  and  the  terms  of the  convertible
preferred  stock  issued in June 2002 may result in the  issuance of  additional
shares at some future date if certain events occur.  Since these events have not
yet occurred,  and therefore  the number of additional  shares is not known,  no
additional  shares have been included in the earnings per share calculation (see
Note H).

     For the three and nine months ended December 31, 2002,  options to purchase
505,000 and 510,000 shares of common stock were not included in the  computation
of diluted earnings per share because the options' exercise prices were not less
than the value of the common shares and would be anti-dilutive.


<PAGE>
                                       7


NOTE D - REVENUE RECOGNITION

     The  Company  recognizes  revenue  when  products  are  shipped  and  title
transfers.  Revenue  includes  certain amounts invoiced to customers for freight
and handling charges.

     The Company  includes the actual cost of freight and  handling  incurred in
cost of sales. The actual cost of freight and handling for the nine months ended
December 31, 2002 and 2001 was $1,223,000 and $1,046,000 respectively.


NOTE E - RESEARCH AND DEVELOPMENT AND PRODUCT DEVELOPMENT

     The Company expenses  product  research and development  costs as incurred.
The Company incurred  approximately  $119,000 and $60,000 during the nine months
ended  December 31, 2002 and 2001  respectively  for  research  and  development
costs.

     All costs incurred subsequent to the completion of research and development
activities  associated with the product's  hardware  components and the software
components  achievement of technological  feasibility are capitalized  until the
product is available  for general  release to customers.  The Company  initially
classifies the construction costs of the first units produced for commercial use
as product development costs prior to transferring these costs to inventory. The
Company capitalized  approximately  $384,000 and $515,000 of product development
costs during the nine months ended December 31, 2002 and 2001 respectively.

     Product  development costs are generally amortized on a straight-line basis
over a five (5) year period. Amortization expense related to product development
costs was $130,000  and $56,000 for the nine months ended  December 31, 2002 and
2001 respectively.

     At March 31, 2002 and December 31, 2002, the Company's  capitalized product
development  costs  included its new  OnDemand(TM)  product,  which  represented
$1,314,000  and  $1,113,000   respectively  of  the  total  capitalized  product
development costs (see Note L).  Manufacturing  costs of approximately  $441,000
were included in the OnDemand capitalized product development costs at March 31,
2002. All manufacturing costs of the OnDemand product were included in inventory
at December 31, 2002. The Company  expects that  approximately  $160,000 will be
expended  during the fourth quarter to complete the  development of new versions
of the OnDemand product.

     The first  OnDemand  machine  was sold in June 2002.  The  second  OnDemand
machine was sold in December of 2002. A third OnDemand  machine was ordered by a
customer in January  2003,  and a deposit of 100% of the ultimate  selling price
was received with the order. Once certain performance specifications are met and
the customer  formally accepts the machine,  the Company will record the revenue
associated with this sale.




<PAGE>
                                       8


NOTE F - LONG-TERM DEBT

         Long-term debt consists of the following:


<TABLE>
<CAPTION>
                                                                                     December 31,       March 31,
                                                                                         2002             2002
                                                                                    -------------    --------------
                                                                                            (In Thousands)
  <S>                                                                                <C>              <C>
  Bank Term Loan payable in installments of interest at 7.5% and principal
    monthly for ten years ending September 1, 2006, with a lump sum payment of
    approximately $7.1 million on that date secured by all tangible and
    intangible assets of the Company.                                                $       0        $   11,449

  Revolving  Line of Credit  due June 26,  2005 plus  interest  payable  at 1%
    above the prime rate (5.75% at December 31, 2002).                                   3,445                 0

  Bank Term Loan payable in monthly  installments  of $83,333 plus interest at
    2.25% above the prime rate (7.0% at December 31, 2002) through June 2004.            1,500                 0

  Bank Term Loan payable in monthly  installments  of $11,667 plus interest at
    1.25% above the prime rate (6.0% at December 31, 2002) through June 2007.              630                 0

  Subordinated Note - Face amount of $4,000,000, less unamortized original issue
    discount of $1,113,000 (see Note H), due June 26, 2007 plus
    interest payable monthly at 14%.                                                     2,887                 0

  Unsecured Note Payable plus interest at 3%, payable in monthly  installments
    of $2,394 through September 2006.                                                      103               122

  Unsecured Note Payable under settlement agreement with State of Florida
    Department of Revenue, payable in monthly installments of $3,500 through
    April 2006.                                                                            136               171

   Other Notes and Agreements                                                               19                38
                                                                                    -------------    --------------
  Total Long -Term Debt                                                                  8,720            11,780
  Less Current Portion                                                                  (1,168)             (968)
                                                                                    -------------    --------------
  LONG-TERM DEBT DUE AFTER 1 YEAR                                                    $   7,552       $    10,812
                                                                                    =============    ==============
</TABLE>



     In June 2002,  the Company repaid the entire  amount,  $11,310,000,  of its
bank term loan with the proceeds of a new revolving line of credit,  term loans,
a  subordinated  note and  convertible  preferred  stock.  The revolving line of
credit allows for  borrowing of up to  $5,000,000  based upon advance rates that
are  applied  to the  Company's  eligible  accounts  receivable  and  inventory.
Interest is payable on the revolving line of credit monthly based on the average
unpaid balance at the prime rate plus 1.0%.

     One term loan in the  amount of  $700,000  is  repayable  in equal  monthly
installments  over a five (5) year term,  plus  interest  at the prime rate plus
1.25%.  Another  term loan in the amount of  $2,000,000  is  repayable  in equal
monthly  installments  over two (2) years plus  interest  at the prime rate plus
2.25% and is subject to an excess cash flow payment provision.


<PAGE>
                                       9


     The subordinated  note in the amount of $4,000,000 is repayable in five (5)
years with  interest  only,  at 14%,  payable  monthly until the maturity of the
note. The subordinated  note is secured by a second lien on all of the assets of
the Company.  In addition,  the  subordinated  note holders were issued  566,517
warrants to purchase  common  stock  exercisable  for ten (10) years at $.01 per
share. (Subject to certain antidilution  provisions.) (See note H.) The relative
value of the  warrants,  and certain  imbedded  features of the  warrants,  were
recorded as part of the stockholders'  equity and reduced the carrying amount of
the subordinated note as an original issue discount. The original issue discount
is  being  amortized  over the five  (5)  year  term of the  subordinated  note.
Amortization expense related to the original issue discount was $127,000 for the
nine months ended December 31, 2002.

     The revolving  line of credit and bank term loans are  collateralized  by a
first security interest in all of the assets of the Company.

     The bank term loans also  contain  provisions  that  require the Company to
make  additional  principal  payments  based upon its excess  cash flow and also
requires  the Company to maintain  certain  financial  ratios and  stockholders'
equity  levels.  In  addition,  certain  provisions  limit the amount of capital
expenditures that the Company can make each year.


NOTE G - CONTINGENCIES

     In November 1998, MTL, a discontinued operation,  received a refund request
in the amount of $1.8 million from  Medicare  Program  Safeguards  ("MPS").  MTL
disputed the refund  request in its response to MPS in December  1998.  To date,
MTL has not received any further correspondence from MPS regarding this matter.

     The Company sold the assets of subsidiaries  LifeServ and MTL during fiscal
2000. The buyers assumed certain  liabilities of these subsidiaries  including a
certain long-term obligation totaling approximately $120,000, as of December 31,
2002, payable to a financial  institution and secured by equipment at a customer
site and a contract receivable. The Company was a guarantor of the obligation at
the time the  obligation  originated  and continues as a guarantor.  In November
2002, the Company  received a notification  from the financial  institution that
the obligation was in default and a demand for payment of approximately $70,000.
At the time the Company  provided its guaranty,  it received an  indemnification
from the  majority  owner of the buyer for any  amounts  that it may have to pay
under terms of the guaranty.  In the event that the Company is required to repay
the  obligation,  it intends to seek  reimbursement  from the owner of the buyer
under the terms of the indemnification.

     Certain creditors of LifeServ have commenced legal actions against LifeServ
seeking  payment of liabilities  assumed by the buyers of LifeServ.  The Company
intends to vigorously  defend these actions and seek  appropriate  remedies from
the buyers.

     The Company is involved in certain claims and legal actions  arising in the
ordinary course of business  including the matters referred to above.  There can
be no assurances that these matters will be resolved on terms  acceptable to the
Company.  In the  opinion  of  management,  based  upon  advice of  counsel  and
consideration  of all facts available at this time, the ultimate  disposition of
these  matters  are  not  expected  to have a  material  adverse  effect  on the
financial position, results of operations or liquidity of the Company.



<PAGE>
                                       10


NOTE H - STOCKHOLDER EQUITY

     In June 2002,  the Company  issued  subordinated  notes to an investor (see
Note F). As part of the  consideration  for the  notes,  the  investor  received
566,517 warrants to purchase common stock  exercisable at $.01 per share for ten
(10) years.

     Also in June 2002, the Company issued 2,000 shares of convertible preferred
stock at $1,000 per share.  The holders of the  convertible  preferred stock are
entitled  to  receive  quarterly  dividends  at the rate of 11% per  annum.  The
dividends are payable in cash or shares of  convertible  preferred  stock at the
Company's option and are cumulative. Through the period ended December 31, 2002,
all dividends due in the amount of  approximately  $113,000 were paid in cash or
accrued. The preferred stock is convertible into 847,457 shares of the Company's
common  stock at $2.36 per share.  The terms of the  preferred  stock  contain a
make-whole  provision that  obligates the Company to pay certain  amounts to the
holders if they do not ultimately receive an amount equal to the price per share
of the common stock on the date they elect to convert the  preferred  stock into
common stock. On the date the convertible  preferred stock was issued,  the fair
market  value of the  Company's  common stock was $2.77 per share based upon the
closing bid on the OTC Bulletin  Board.  The difference  between the fair market
value of the shares and the conversion price of the convertible  preferred stock
represented a constructive dividend to the holders of the preferred stock in the
amount of $347,000 (See Note C).

     The terms of the warrant and convertible preferred stock agreements contain
certain  antidilution   provisions.   The  warrant  agreement  also  contains  a
make-whole  provision that  obligates the Company to pay certain  amounts to the
holders  of  the  warrants  and  convertible  preferred  stock  if  they  do not
ultimately receive an amount equal to the price per share of the common stock on
the date they  exercise  their right to purchase the common shares that underlie
the warrants.  The warrant agreement also contains a provision that may obligate
the Company to pay certain  amounts to the holders of the  warrants in the event
there is a change in control of the voting common stock of the Company, if there
is a sale of the  Company,  or if there is a public  offering  of the  Company's
common stock.

     The make-whole provision and certain antidilution provisions also represent
a contingent  beneficial  conversion feature of the convertible preferred stock.
The effect of this  feature may result in the issuance of  additional  shares at
some future date;  however,  since the issuance of these shares is contingent on
future  events,  the effect of this  feature  will be  recorded  at the time the
events occur.

     In the event the Company is required to make payments to the holders of the
warrants  and/or  preferred  stock,  it may elect to issue  additional  warrants
and/or  preferred  stock  in lieu  of  cash  payment.  Although  the  make-whole
provision  and  other  provisions  of  the  warrant  agreement  and  convertible
preferred stock agreement provide for a maximum of 12,500,000 shares that may be
issued pursuant to those provisions,  based upon current conditions, the Company
believes it is unlikely that the maximum number of shares would be issued.

     The Company has determined the value of the warrants and the make-whole and
other  provisions of the warrants and has recorded this amount as a component of
its stockholders'  equity. This amount,  $1,240,000 also represents the original
issue   discount  that  will  be  amortized  over  the  five-year  term  of  the
subordinated note.

     The Company also issued,  to its financial  advisors,  125,000  warrants to
purchase  common  stock  as part of the fees  related  to the  above  referenced
financing.  The warrants are fully  exercisable  for five (5) years at $1.50 per
share.  The value of these  warrants,  $324,000,  was determined  based upon the
value of the Company's  common stock on the date the warrants  were issued.  The
Company recorded the value of the warrants as a component of its financing costs
incurred (see Note I).


<PAGE>
                                       11



NOTE I - FINANCING COSTS

     The Company incurred approximately $1,458,000 of financing costs during the
nine months ended December 31, 2002,  including the value of the warrants issued
to the  Company's  financial  advisors  related to obtaining  certain  financing
described  in Notes F and H. The  financing  costs were  allocated  between  the
components  of the financing  that  represented  debt and equity.  The financing
costs that were allocated to the debt proceeds,  $1,090,000,  have been recorded
as an other asset and will be amortized  over the repayment  term of the various
loans and notes. The financing costs that were allocated to the equity proceeds,
$368,000, have been recorded as a reduction of the equity proceeds. Amortization
expense  related to the  financing  costs was $178,000 for the nine months ended
December 31, 2002.


NOTE J - NEW ACCOUNTING PRONOUNCEMENTS

     On July 20, 2001, the Financial  Accounting  Standards  Board (FASB) issued
Statement of Financial Accounting  Standards (SFAS) 141, Business  Combinations,
and SFAS 142,  Goodwill and  Intangible  Assets.  SFAS 141 is effective  for all
business  combinations  completed after June 30, 2002. SFAS 142 is effective for
the fiscal year beginning  April 1, 2002;  however,  certain  provisions of that
Statement apply to goodwill and other intangible assets acquired between July 1,
2001 and the effective date of SFAS 142.

     In August 2001, the FASB issued SFAS No. 144, Accounting for the Impairment
or Disposal of Long-Lived Assets. This statement addresses financial  accounting
and reporting for the impairment or disposal of long-lived assets and supersedes
FASB Statement No. 121,  Accounting for the Impairment of Long-Lived  Assets and
for  Long-Lived  Assets to be Disposed Of. The  provisions  of the statement are
effective  for  financial  statements  issued for fiscal years  beginning  after
December 15, 2001.

     The  Company's  initial  analysis  of the  effect  of these  new  standards
indicates that the adoption of the standards will not have a material  impact on
its financial  statements.  As of March 31, 2001 and 2002 and December 31, 2002,
no amounts of goodwill are recorded.


NOTE K - RECLASSIFICATIONS

     Certain  reclassifications  were made to the  December  31, 2001  financial
statements to conform to the 2002 presentations.


<PAGE>
                                       12


NOTE L - OTHER ASSETS

         Other assets consist of the following:

<TABLE>
<CAPTION>
                                                                 December 31,               March 31,
                                                                     2002                     2002
                                                               ---------------          ----------------
                                                                            (In Thousands)
          <S>                                                  <C>                      <C>

          Product Development                                  $      1,808             $       2,202
              Less Accumulated Amortization                            (427)                     (315)
                                                               ----------------         -----------------
                                                                      1,381                     1,887
                                                               ----------------         -----------------

          Patents                                                     1,228                     1,196
              Less Accumulated Amortization                            (787)                     (725)
                                                               ----------------         -----------------
                                                                        441                       471
                                                               ----------------         -----------------

          Financing Costs                                             1,090                         0
              Less Accumulated Amortization                            (178)                        0
                                                               ----------------         -----------------
                                                                        912                         0
                                                               ----------------         -----------------

          Other                                                         210                       190
              Less Accumulated Amortization                            (102)                      (71)
                                                               ----------------         -----------------
                                                                        108                       119
                                                               ----------------         -----------------

          Total Other Assets Net                               $      2,842             $       2,477
                                                               ================         =================
</TABLE>


     During the nine months ended  December 31, 2002,  the Company  reclassified
approximately  $682,000  and  $89,000  of product  development  costs from other
assets to inventory and fixed assets, respectively.



<PAGE>
                                       13



                MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
                     MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS
              FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2002


ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

     This Form 10-Q contains  forward-looking  statements  within the meaning of
that term in Section  27A of the  Securities  Act of 1933 and Section 21E of the
Securities  Exchange  Act of 1934.  Additional  written or oral  forward-looking
statements  may be made by the Company  from time to time,  in filings  with the
Securities and Exchange  Commission or otherwise.  Statements  contained  herein
that are not historical  facts are  forward-looking  statements made pursuant to
the safe harbor  provisions  described  above.  Forward-looking  statements  may
include,  but are not limited to,  projections  of  revenues,  income or losses,
capital  expenditures,  plans for future  operations,  the elimination of losses
under certain  programs,  financing  needs or plans,  compliance  with financial
covenants  in loan  agreements,  plans for sale of assets or  businesses,  plans
relating to products or services of the  Company,  assessments  of  materiality,
predictions of future events and the effects of pending and possible litigation,
as well as assumptions relating to the foregoing. In addition, when used in this
discussion,  the  words  "anticipates",   "estimates",   "expects",   "intends",
"believes",  "plans" and variations thereof and similar expressions are intended
to identify forward-looking statements.

     Forward-looking   statements   are   inherently   subject   to  risks   and
uncertainties,  some of which can be  predicted or  quantified  based on current
expectations.  Consequently,  future  events and  actual  results  could  differ
materially  from  those  set  forth  in,  contemplated  by,  or  underlying  the
forward-looking  statements  contained  herein.  Statements in Quarterly Report,
particularly  in "Item 2.  Management's  Discussion  and  Analysis of  Financial
Condition  and  Results  of  Operations"  and  Notes to  Condensed  Consolidated
Financial Statements,  describe factors,  among others, that could contribute to
or cause such differences.  Other factors that could contribute to or cause such
differences  include,  but  are  not  limited  to,  unanticipated  increases  in
operating costs, labor disputes,  capital  requirements,  increases in borrowing
costs, product demand, pricing, market acceptance,  intellectual property rights
and  litigation,  risks in product  and  technology  development  and other risk
factors detailed in the Company's Securities and Exchange Commission filings. In
particular  any  comments  regarding  possible  default  waivers  related to the
Company's loan agreement are forward-looking statements.

     Readers are  cautioned not to place undue  reliance on any  forward-looking
statements contained herein, which speak only as of the date hereof. The Company
undertakes  no  obligation  to publicly  release the result of any  revisions of
these  forward-looking  statements  that  may  be  made  to  reflect  events  or
circumstances  after the date hereof or to reflect the  occurrence of unexpected
events.

RESULTS OF OPERATIONS

Three Months Ended December 31, 2002 and 2001

     Net sales for the three months ended December 31, 2002  increased  24.2% to
$7.7 million from $6.2 million  during the same period the prior year. Net sales
increased primarily as a result of an increase in the amount of disposable punch
cards sold to new and  existing  customers.  In  addition,  the Company sold one
OnDemand (TM) machine  during the three months ended  December 31, 2002.  Prices
for  disposable  products  were stable  compared to the prior year.  The Company
anticipates  that pricing on disposables  will continue to be stable through the
balance of the fiscal  year.  The volume of  disposable  cards and  machines  is
currently  anticipated  to continue  to grow as a result of the  addition of new
customers in existing and new markets.

     Cost of sales for the three months ended December 31, 2002 increased  24.3%
to $4.6 million from $3.7 million during the same period the prior year. Cost of
sales as a percentage of sales  remained  constant at 59.7% compared to the same
period the prior year.  The  increase in cost of sales  primarily  results  from
increased costs associated with higher revenue. Cost of sales as a percentage of
sales remained  constant  primarily due to manufacturing  efficiencies  achieved
that offset material cost increases.


<PAGE>
                                       14


     Selling,  general and  administration  expenses  for the three months ended
December 31, 2002 increased  50.0% to $1.8 million from $1.2 million in the same
period  during  the prior  year  primarily  due to  increased  personnel  costs,
training,  research and development  expenditures  and costs associated with the
Company's operations in the United Kingdom. In addition, during the three months
ended December 31, 2001,  the Company  reduced its estimated bad debt reserve by
$89,000.  The Company  reviewed the estimated bad debt reserve  during the three
months ended December 31, 2002 and did not make a reduction.

     Depreciation and amortization  expenses for the three months ended December
31, 2002  increased  7.0% to $243,000 from  $227,000  during the same period the
prior year. The increase results  primarily from the fact that the Company began
to amortize  the  capitalized  development  costs  associated  with the OnDemand
product during its second quarter ended September 30, 2002.

     Other  expenses  related  to the June  2002  refinancing  of the  Company's
long-term  debt were $151,000  during the three months ended  December 31, 2002.
These expenses  resulted from the  amortization of certain costs associated with
the  financing  ($89,000)  as well as the  amortization  of the  original  issue
discount  associated  with  the  subordinated  debt  portion  of the  financing,
($62,000).

     Interest  expense  for the three  months  ended  December  31, 2002 did not
change from $219,000 to $219,000 during the same period the prior year. Although
the Company reduced its total debt as a result of the June 2002 refinancing, the
effective  interest rate on the  outstanding  debt  increased as a result of the
financing.

     Income tax  expense  decreased  18.4% to $261,000  during the three  months
ended  December  31,  2002  compared to $320,000  the prior year.  The  decrease
results from lower income tax expense associated with lower income.

Nine Months Ended December 31, 2002 and 2001

     Net sales for the nine months ended  December 31, 2002  increased  17.7% to
$21.3  million  from $18.1  million  during the same period the prior year.  Net
sales increased primarily as a result of an increase in the amount of disposable
punch  cards  and  machines  sold  to new and  existing  customers.  Prices  for
disposable products were stable compared to the prior year. In addition, two (2)
OnDemand  machines were sold during the nine months ended December 31, 2002. The
Company  anticipates  that  pricing on  disposables  will  continue to be stable
through  the  balance of the fiscal  year.  The volume of  disposable  cards and
machines  is  currently  anticipated  to  continue  to grow as a  result  of the
addition of new customers in existing and new markets.

     Cost of sales for the nine months ended December 31, 2002  increased  21.5%
to $13.0 million from $10.7 million during the same period the prior year.  Cost
of sales as a percentage of sales  increased to 61.0% from 59.1% during the same
period the prior year.  The  increase in cost of sales  primarily  results  from
increased  costs  associated  with higher  revenue.  The increase in the cost of
sales as a percentage  of sales results  primarily  from higher  overhead  costs
incurred  compared  to the same  period the prior  year.  The  higher  costs are
related  primarily  to the  addition  of  personnel  in  factory  operations  in
anticipation  of expected  growth in revenue,  as well as costs  associated with
production of the OnDemand machines.

     Selling,  general and  administration  expenses  for the nine months  ended
December 31, 2002 increased  23.1% to $4.8 million from $3.9 million in the same
period  during  the prior  year  primarily  due to  increased  personnel  costs,
training,  research and development  expenditures and marketing costs associated
with new products  including the OnDemand  machine and expenses  associated with
the Company's  operations in the United  Kingdom.  In addition,  during the nine
months ended  December  31, 2001,  the Company  reduced its  estimated  bad debt
reserve by $89,000.  The Company  reviewed the estimated bad debt reserve during
the nine months ended December 31, 2002 and did not make a reduction.




<PAGE>
                                       15


     Depreciation and  amortization  expenses for the nine months ended December
31, 2002 decreased slightly to $679,000 from $684,000 during the same period the
prior year. The decrease results primarily from the fact that certain assets are
now fully depreciated when compared to the same period the prior year.

     Other  expenses  related  to the June  2002  refinancing  of the  Company's
long-term  debt were  $305,000  during the nine months ended  December 31, 2002.
These expenses  resulted from the  amortization of certain costs associated with
the  financing  ($178,000)  as well as the  amortization  of the original  issue
discount  associated  with  the  subordinated  debt  portion  of  the  financing
($127,000).

     Interest expense for the nine months ended December 31, 2002 decreased 4.6%
to $668,000  from $700,000  during the same period the prior year.  The decrease
results from a reduction in  outstanding  debt  resulting  from regular  monthly
principal  payments made according to the terms of the Company's loan agreements
as well as a reduction in total  outstanding  debt that  resulted  from the June
2002 refinancing.

     Income tax expense decreased 12.2% to $699,000 during the nine months ended
December 31, 2002 compared to $796,000 the prior year. The decrease results from
lower income tax expense associated with lower income.

LIQUIDITY AND CAPITAL RESOURCES

     During the nine months ended  December 31, 2002, the Company had net income
of $1,150,000 compared to net income of $1,356,000 the prior year. Cash provided
by operating activities was $2,077,000 during the nine months ended December 31,
2002 compared to $2,299,000  provided in the prior year. The Company had working
capital of $4,228,000 at December 31, 2002.

     The  decrease in cash  provided  by  operating  activities  during the nine
months ended  December  31, 2002  compared to the same period the prior year was
primarily  due to an  increase in accounts  receivable  resulting  from the high
level sales in the month of December 2002.

     Investing  activities used $1,178,000 during the nine months ended December
31, 2002 compared to $1,274,000 the prior year. The decrease  results  primarily
from a reduction in expenditures  for capitalized  development  costs related to
the OnDemand machine.

     Financing  activities used $1,187,000 during the nine months ended December
31, 2002  compared to $955,000 the prior year.  The increase  results  primarily
from the costs associated with the refinance of the Company's  long-term debt in
June 2002.

     In June 2002,  the Company repaid the entire  amount,  $11,310,000,  of its
bank term  loan  with cash on hand,  the  proceeds  of a new  revolving  line of
credit,  term loans, a subordinated  note and convertible  preferred  stock. The
revolving  line of credit allows for  borrowing of up to  $5,000,000  based upon
advance rates that are applied to the Company's eligible accounts receivable and
inventory.  Interest is payable on the revolving line of credit monthly based on
the average unpaid balance at the prime rate plus 1.0%.

     One term loan in the  amount of  $700,000  is  repayable  in equal  monthly
installments  over a five (5) year term,  plus  interest  at the prime rate plus
1.25%.  Another  term loan in the amount of  $2,000,000  is  repayable  in equal
monthly  installments  over two (2) years plus  interest  at the prime rate plus
2.25% and is subject to an excess cash flow payment provision.

     The  revolving  line of  credit  and the  term  loans  are  secured  by the
Company's accounts receivable,  inventory, machinery and equipment and all other
assets of the Company.


<PAGE>
                                       16


     The subordinated  note in the amount of $4,000,000 is repayable in five (5)
years with  interest  only,  at 14%,  payable  monthly until the maturity of the
note. The subordinated  note is secured by a second lien on all of the assets of
the Company.  In addition,  the  subordinated  note holders were issued  566,517
warrants to purchase  common  stock  exercisable  for ten (10) years at $.01 per
share. (Subject to certain antidilution provisions.)

     The Company  issued 2,000 shares of convertible  preferred  stock at $1,000
per share.  The  holders of the  convertible  preferred  stock are  entitled  to
receive  quarterly  dividends at the rate of 11% per annum.  The  dividends  are
payable  in cash or shares of  convertible  preferred  stock,  at the  Company's
option,  and are  cumulative.  The preferred  stock is convertible  into 847,457
shares of the  Company's  common  stock at $2.36 per share.  (Subject to certain
antidilution provisions.)

     The warrant  agreement  and the terms of the  convertible  preferred  stock
contain a make-whole provision that obligates the Company to pay certain amounts
to the holders of the warrants and  convertible  preferred  stock if they do not
ultimately receive an amount equal to the price per share of the common stock on
the date they  exercise  their right to purchase the common shares that underlie
the warrants and the convertible  preferred  stock.  The warrant  agreement also
contains a provision that may obligate the Company to pay certain amounts to the
holders  of the  warrants  in the event that there is a change in control of the
voting  common  stock of the Company,  if there is a sale of the Company,  or if
there is a public offering of the Company's common stock.

     In the event that the Company is  required to make  payments to the holders
of the  warrants  and/or  preferred  stock,  it may  elect to  issue  additional
warrants  and/or  preferred  stock  in  lieu  of a cash  payment.  Although  the
make-whole   provision  and  other  provisions  of  the  warrant  agreement  and
convertible preferred stock agreement provide for a maximum of 12,500,000 shares
that may be issued pursuant to those provisions,  based upon current conditions,
the Company  believes it is unlikely that the maximum  number of shares would be
issued.

     The revolving  line of credit,  the term loans and the  subordinated  notes
each contain certain financial covenants that, among other things,  requires the
maintenance  of  certain  financial   ratios,   limits  the  amount  of  capital
expenditures and requires the Company to obtain the lenders approval for certain
matters.

     The Company's  short-term and long-term liquidity is primarily dependent on
its ability to generate cash flow from  operations.  Inventory levels may change
significantly  if the Company is  successful  in selling its  OnDemand  machine.
Increases  in net  sales may  result  in  corresponding  increases  in  accounts
receivable.  Cash  flow  from  operations  and  borrowing  availability  on  the
revolving  line of credit is  anticipated  to support an  increase  in  accounts
receivable and inventory.

     The Company has several new product development  projects underway that are
expected to be funded by cash flow from operations. These projects are monitored
on a regular basis to attempt to ensure that the  anticipated  costs  associated
with them do not exceed the  Company's  ability to fund them from cash flow from
operations.

     The Company  believes that the cash generated from  operations  during this
fiscal  year is  expected to be  sufficient  to meet its  capital  expenditures,
product  development,  working capital needs and the principal payments required
by its loan agreements.



<PAGE>
                                       17


ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

     While we had no holdings of derivative  financial or commodity  investments
at December  31,  2002,  we are exposed to  financial  market  risks,  including
changes in  interest  rates.  Although  certain of our  borrowings  bear a fixed
interest  rate,  our  borrowings  under our revolving line of credit and certain
term loans bear interest at a variable rate based upon the prime rate.


ITEM 4.  CONTROLS AND PROCEDURES

          A.   Evaluation of Disclosure Controls and Procedures

               Disclosure  controls and  procedures  are designed to ensure that
               information  required to be  disclosed  in the  reports  filed or
               submitted   under  the  Exchange  Act  is  recorded,   processed,
               summarized and reported, within the time periods specified in the
               SEC's  rules  and  forms.   Disclosure  controls  and  procedures
               include, without limitation,  controls and procedures designed to
               ensure that  information  required to be disclosed in the reports
               filed under the Exchange Act is accumulated  and  communicated to
               management,  including  the  Chief  Executive  Officer  and Chief
               Financial  Officer,  as  appropriate,  to allow timely  decisions
               regarding  required  disclosure.  Within the 90 days prior to the
               filing of this  report,  the Company  carried out an  evaluation,
               under the supervision and with the participation of the Company's
               management,  including the Company's Chief Executive  Officer and
               Chief Financial  Officer,  of the effectiveness of the design and
               operation of the Company's disclosure controls and procedures (as
               defined in Exchange Act Rules  13a-14(c)  and  15d-14(c)).  Based
               upon  and as of the  date of  that  evaluation,  Chief  Executive
               Officer and Chief Financial  Officer concluded that the Company's
               disclosure  controls and  procedures are effective to ensure that
               information  required to be  disclosed in the reports the Company
               files and submits  under the Exchange Act is recorded,  processed
               summarized and reported as and when required.

          B.   Changes in Internal Controls

               There  were no  significant  changes  in the  Company's  internal
               controls or other factors that could  significantly  affect those
               controls  subsequent  to the date of the  Company's  most  recent
               evaluation  including  any  corrective  actions  with  regard  to
               significant deficiencies and material weaknesses.




<PAGE>
                                       18




PART II - OTHER INFORMATION


Item 6.  Exhibits and Reports on Form 8-K


         A. Reports on Form 8K

            None

         B. Exhibit 99.1

            Certification Pursuant to 18 U.S.C. ss.1350

         C. Exhibit 99.2

            Certification Pursuant to 18 U.S.C. ss.1350


Signatures


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                     MEDICAL TECHNOLOGY SYSTEMS, INC.


  Date:  February 13, 2003           By: /s/ Michael P. Conroy
         ------------------          -------------------------------------------
                                     Michael P. Conroy
                                     Vice President & Chief Financial Officer




Date:  February 13, 2003             By:     /s/ Mark J. Connolly
       --------------------          -------------------------------------------
                                     Mark J. Connolly
                                     Principal Accounting Officer and Controller





<PAGE>
                                       19


                                 CERTIFICATIONS

I, Todd E. Siegel, certify that:

1.   I have reviewed this  quarterly  report on Form 10-Q of Medical  Technology
     Systems, Inc.;

2.   Based on my knowledge,  this  quarterly  report does not contain any untrue
     statement of a material fact or omit to state a material fact  necessary to
     make the statements  made, in light of the  circumstances  under which such
     statements  were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my  knowledge,  the  financial  statements,  and  other  financial
     information  included  in this  quarterly  report,  fairly  present  in all
     material respects the financial  condition,  results of operations and cash
     flows of the  registrant  as of, and for,  the  periods  presented  in this
     quarterly report;

4.   The  registrant's  other  certifying  officers  and I are  responsible  for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     a)   designed  such  disclosure  controls  and  procedures  to ensure  that
          material  information  relating  to  the  registrant,   including  its
          consolidated subsidiaries,  is made known to us by others within those
          entities,  particularly  during  the  period in which  this  quarterly
          report is being prepared;

     b)   evaluated the  effectiveness of the registrant's  disclosure  controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     c)   presented  in  this  quarterly   report  our  conclusions   about  the
          effectiveness  of the disclosure  controls and procedures based on our
          evaluation as of the Evaluation Date;

5.   The registrant's other certifying  officers and I have disclosed,  based on
     our most recent  evaluation,  to the  registrant's  auditors  and the audit
     committee of  registrant's  board of directors (or persons  performing  the
     equivalent function):

     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which could  adversely  affect the  registrant's  ability to
          record,  process,   summarize  and  report  financial  data  and  have
          identified for the  registrant's  auditors any material  weaknesses in
          internal controls; and

     b)   any fraud, whether or not material,  that involves management or other
          employees who have a  significant  role in the  registrant's  internal
          controls; and

6.   The  registrant's  other  certifying  officers and I have indicated in this
     quarterly report whether or not there were significant  changes in internal
     controls  or in other  factors  that could  significantly  affect  internal
     controls  subsequent to the date of our most recent  evaluation,  including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.


Date: February 13, 2003                    By:  /s/ Todd E. Siegel
      -----------------                    -------------------------------------
                                           Todd E. Siegel
                                           President & Chief Executive Officer


<PAGE>
                                       20


I, Michael P. Conroy, certify that:

1.   I have reviewed this  quarterly  report on Form 10-Q of Medical  Technology
     Systems, Inc.;

2.   Based on my knowledge,  this  quarterly  report does not contain any untrue
     statement of a material fact or omit to state a material fact  necessary to
     make the statements  made, in light of the  circumstances  under which such
     statements  were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my  knowledge,  the  financial  statements,  and  other  financial
     information  included  in this  quarterly  report,  fairly  present  in all
     material respects the financial  condition,  results of operations and cash
     flows of the  registrant  as of, and for,  the  periods  presented  in this
     quarterly report;

4.   The  registrant's  other  certifying  officers  and I are  responsible  for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     a)   designed  such  disclosure  controls  and  procedures  to ensure  that
          material  information  relating  to  the  registrant,   including  its
          consolidated subsidiaries,  is made known to us by others within those
          entities,  particularly  during  the  period in which  this  quarterly
          report is being prepared;

     b)   evaluated the  effectiveness of the registrant's  disclosure  controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     c)   presented  in  this  quarterly   report  our  conclusions   about  the
          effectiveness  of the disclosure  controls and procedures based on our
          evaluation as of the Evaluation Date;

5.   The registrant's other certifying  officers and I have disclosed,  based on
     our most recent  evaluation,  to the  registrant's  auditors  and the audit
     committee of  registrant's  board of directors (or persons  performing  the
     equivalent function):

     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which could  adversely  affect the  registrant's  ability to
          record,  process,   summarize  and  report  financial  data  and  have
          identified for the  registrant's  auditors any material  weaknesses in
          internal controls; and

     b)   any fraud, whether or not material,  that involves management or other
          employees who have a  significant  role in the  registrant's  internal
          controls; and

6.   The  registrant's  other  certifying  officers and I have indicated in this
     quarterly report whether or not there were significant  changes in internal
     controls  or in other  factors  that could  significantly  affect  internal
     controls  subsequent to the date of our most recent  evaluation,  including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.


Date:  February 13, 2003               By:     /s/ Michael P. Conroy
       ------------------              -----------------------------------------
                                       Michael P. Conroy
                                       Vice President & Chief Financial Officer



<PAGE>
                                       21



Exhibit 99.1


CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Medical Technology Systems, Inc. (the
"Company") on Form 10-Q for the period ended December 31, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the "Form 10-Q"), I, Todd
E.  Siegel,  President  and Chief  Executive  Officer of the  Company,  certify,
pursuant  to  18  U.S.C.   ss.1350,   as  adopted  pursuant  to  ss.906  of  the
Sarbanes-Oxley Act of 2002, that:

     (1)  The Form 10-Q fully complies with the requirements of Section 13(a) or
          15(d)  of the  Securities  Exchange  Act of  1934  (15  U.S.C.  78m or
          78o(d)); and

     (2)  The  information  contained in the Form 10-Q fairly  presents,  in all
          material respects,  the financial  condition and results of operations
          of the Company.


Dated:  February 13, 2003

/s/ Todd E. Siegel
-----------------------------------------
Todd E. Siegel
President and Chief Executive Officer


<PAGE>
                                       22



Exhibit 99.2


CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Medical Technology Systems, Inc. (the
"Company") on Form 10-Q for the period ended December 31, 2002 as filed with the
Securities  and Exchange  Commission  on the date hereof (the "Form  10-Q"),  I,
Michael P. Conroy,  Vice President and Chief  Financial  Officer of the Company,
certify,  pursuant to 18 U.S.C.  ss.1350,  as adopted  pursuant to ss.906 of the
Sarbanes-Oxley Act of 2002, that:

     (1)  The Form 10-Q fully complies with the requirements of Section 13(a) or
          15(d)  of the  Securities  Exchange  Act of  1934  (15  U.S.C.  78m or
          78o(d)); and

     (2)  The  information  contained in the Form 10-Q fairly  presents,  in all
          material respects,  the financial  condition and results of operations
          of the Company.


Dated:  February 13, 2003


/s/ Michael P. Conroy
-------------------------------------------
Michael P. Conroy
Vice President & Chief Financial Officer